Products
Puxitatug Biosimilar Monoclonal Antibody (B7-H4) for Research
Cat No.: GMP-Bios-INN-1351
Anti-VTCN1/B7H4 therapeutic antibody (Pre-made Puxitatug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Puxitatug (development code AZD-8205) is a monoclonal antibody targeting B7-H4 (VTCN1). It is developed by AstraZeneca for Solid tumours in Phase I/II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1351-1mg | 1mg | 3090 |
| GMP-Bios-INN-1351-10mg | 10mg | |
| GMP-Bios-INN-1351-100mg | 100mg | |
| GMP-Bios-INN-1351-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Puxitatug biosimilar, Whole mAb, Anti-VTCN1/B7H4 Antibody: Anti-B7‑H4/B7-H4/VTCN1/V-set domain-containing T-cell activation inhibitor 1 therapeutic antibody |
| INN Name | Puxitatug |
| Target | VTCN1/B7H4 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | AstraZeneca |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
